Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
The Covid-19 pandemic is expected to cause a drastic decline in cash usage due to the risk of contamination. “Over the past six to eight months, we’ve seen the use of cash decline even further, and that’s a trend I think that we’re going to see continue,” said Jodie Kelley, CEO of Electronic Transactions Association….
Brenda Vingiello, Sand Hill Global Advisors CIO, Bryn Talkington, Requisite Capital Management managing partner, Jim Lebenthal, Cerity Partners chief equity strategist, and Josh Brown, Ritholtz Wealth Management CEO, join CNBC’s ‘Halftime Report’ to share their final trades.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell CNBC’s Leslie Picker joins ‘Closing Bell’ to report on BlackRock’s plan to cut 3% of it’s global workforce. 01:27 Tue, Jan 9 20244:59 PM EST
CNBC’s Eamon Javers joins ‘Power Lunch’ to discuss the SEC and X investigating a fake SEC post.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Hertz CEO Stephen Scherr joins ‘Squawk on the Street’ to discuss news of the company cutting one-third of its electric vehicle fleet over the year, what’s behind the EV selloff, state of the EV rental market, consumer trends, 2024 outlook, and more….
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email North Korea claims they successfully tested a “miniaturized” hydrogen bomb. So, what exactly is an H-bomb? 01:23 Thu, Jan 7 20169:00 AM EST Nina Raja